Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vantia Therapeutics Ltd.

This article was originally published in Start Up

Executive Summary

Vantia launched in 2007 around small-molecule assets spun out of Ferring Pharmaceuticals, and it's rapidly advancing its pipeline in urology, pain, inflammation and other diseases. It has a Phase II vasopressin 2 agonist for nocturia, a Phase II vasopressin antagonist for dysmenorrhea, and several earlier-stage research programs.
Advertisement

Related Content

Vantia Tops Up With £4 mill Series B To Pursue Nocturia And Dysmenorrhea
Vantia Tops Up With £4 mill Series B To Pursue Nocturia And Dysmenorrhea
Start-Up Previews (10/2009)
Start-Up Previews (10/2009)

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC091872

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel